| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
SVP, CCO | CCO
1 company
Faulkingham Dell serves as a SVP, CCO at AKBA. Across recent SEC filings that breaks down to 0 buys and 6 sells. Those positions are worth an estimated $377K at current prices.
Historically, Faulkingham Dell's trades have earned a strong insider score of 70/100 across 4 rated trades. Over a 12-month horizon, 100.0% of those trades were profitable, with an average 12-month return of +58.6%.
The biggest single holding is AKBA (~$377K) as SVP, CCO. The recent filings there lean toward selling, a net 27,311 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 1, 2022 | AKBA Akebia Therapeutics, Inc. | SVP, CCO | Sell | 13,184 | $2.16 | $28,515.49 | -7.0% | -82.8% | -57.4% | |
| Apr 1, 2021 | AKBA Akebia Therapeutics, Inc. | SVP, CCO | Sell | 952 | $3.40 | $3,236.80 | -0.7% | +13.8% | -79.9% | |
| Mar 1, 2021 | AKBA Akebia Therapeutics, Inc. | CCO | Sell | 6,749 | $3.40 | $22,920.28 | -5.0% | +1.3% | -36.1% | |
| Jun 1, 2020 | AKBA Akebia Therapeutics, Inc. | CCO | Sell | 6,426 | $11.58 | $74,413.08 | -8.0% | - | - |